A new legal challenge has emerged in the ongoing battle over intellectual property rights related to mRNA vaccine technology. BioNTech SE has filed a lawsuit against Moderna Inc., alleging that Moderna’s Spikevax COVID-19 vaccine infringes on a key patent held by BioNTech. The suit centers on a specific mRNA vaccine design that utilizes only essential portions of the coronavirus spike protein, a technique BioNTech says it pioneered during the development of its Comirnaty vaccine in partnership with Pfizer Inc.
The lawsuit, filed in federal court, claims that Moderna’s mNexspike vaccine violates U.S. Patent No. 12,133,899. This patent, according to BioNTech, covers a streamlined mRNA design that proved crucial in creating an effective COVID-19 vaccine. The dispute highlights the complex landscape of intellectual property surrounding the rapid development of COVID-19 vaccines and the significant financial stakes involved.
Moderna acknowledged the lawsuit in a statement, asserting its intention to vigorously defend its position. “Moderna is aware of the litigation and will defend ourselves against these claims,” a Moderna spokesperson said in an emailed statement. The company has previously faced similar patent challenges and maintains that its technology is independently developed and does not infringe on the intellectual property of others.
This legal action is the latest development in a series of patent disputes between the two companies. The core of the disagreement revolves around differing approaches to mRNA vaccine design. BioNTech’s patented technology focuses on using only the necessary components of the spike protein, potentially simplifying manufacturing and improving vaccine efficacy. Moderna’s approach, while also effective, is now being challenged as potentially relying on BioNTech’s foundational function.
BioNTech’s Patent and the mRNA Vaccine Design
The patent at the heart of the dispute, U.S. Patent No. 12,133,899, details a specific method for constructing mRNA vaccines that target the coronavirus spike protein. According to BioNTech, this design allows for a more efficient and targeted immune response. The company argues that Moderna’s mNexspike vaccine utilizes this same design, thereby infringing on its intellectual property rights. The development of this streamlined mRNA design was a critical step in the creation of the Comirnaty vaccine, developed in partnership with Pfizer, which has been widely administered globally. As of February 2026, the Pfizer-BioNTech vaccine remains a key tool in combating COVID-19, as detailed by Wikipedia.
A History of Patent Disputes
The current lawsuit is not an isolated incident. Moderna and Pfizer/BioNTech have been embroiled in legal battles over vaccine technology since 2022. These disputes extend beyond the United States, with cases also filed in Germany, the United Kingdom, the Netherlands, Ireland, and Belgium. A recent ruling in the United Kingdom, as reported by Reuters on August 1, 2025, favored Moderna, upholding a patent covering modifications of mRNA used in its vaccines. However, this ruling doesn’t preclude further challenges, as evidenced by BioNTech’s new lawsuit. A July 2, 2024, High Court of the United Kingdom decision, as discussed by Harvard Law School’s Petrie-Flom Center, found that Moderna was permitted to revoke a pledge not to enforce its patents before the end of the WHO-declared pandemic.
Implications for the Future of mRNA Technology
The outcome of these legal battles could have significant implications for the future of mRNA vaccine technology and the pharmaceutical industry. A ruling in favor of BioNTech could potentially lead to licensing agreements or financial compensation for the company. Conversely, a victory for Moderna would solidify its position as an independent innovator in the mRNA space. The ongoing patent dispute, as analyzed in Frontiers in Bioengineering and Biotechnology, underscores the complexities of intellectual property rights in the context of rapid scientific advancements. The legal proceedings are closely watched by industry experts and investors, as they could shape the competitive landscape of vaccine development for years to arrive.
The legal process will likely be lengthy and complex, involving detailed examination of scientific data and legal arguments. The court will need to determine whether Moderna’s vaccine truly infringes on BioNTech’s patented technology and, if so, what the appropriate remedy should be. The case is expected to draw significant attention from the scientific and legal communities, as it addresses fundamental questions about innovation and intellectual property in the field of mRNA vaccines.
Disclaimer: This article provides informational content only and should not be considered medical or legal advice. Consult with a qualified healthcare professional or legal expert for personalized guidance.
What are your thoughts on the role of patents in accelerating or hindering vaccine development? Share your perspective in the comments below.
